Revvity (RVTY) reported $772.06 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 5.9%. EPS of $1.70 for the same period compares to $1.42 a year ago.
The reported revenue represents a surprise of +0.02% over the Zacks Consensus Estimate of $771.9 million. With the consensus EPS estimate being $1.63, the EPS surprise was +4.29%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Revvity performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic revenue growth - Total: 4% versus the five-analyst average estimate of 2.4%.
- Organic revenue growth - Life Sciences: 0% versus 1% estimated by three analysts on average.
- Organic revenue growth - Diagnostics: 7% versus the three-analyst average estimate of 3.6%.
- Net Sales- Life Sciences: $381.99 million compared to the $376.21 million average estimate based on four analysts. The reported number represents a change of +13.6% year over year.
- Net Sales- Diagnostics: $390.07 million versus $385.54 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -0.8% change.
View all Key Company Metrics for Revvity here>>>
Shares of Revvity have returned +10.9% over the past month versus the Zacks S&P 500 composite's +0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Revvity Inc. (RVTY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
